Lu-PSMA Radioligand Therapy for advanced Prostate Cancer

被引：0
|
作者：
Derlin, T. [1 ]
机构：
[1] Hannover Med Sch, Zentrum Radiol, Klin Nukl Med, Carl Neuberg Str 1, D-30625 Hannover, Germany
来源：
RADIOLOGE | 2017年 / 57卷 / 12期
关键词：
D O I：
10.1007/s00117-017-0283-2
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
[No abstract available]
引用
收藏
页码：1001 / 1003
页数：3
相关论文
共 50 条
  • [41] PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
    Seifert, Robert
    Kessel, Katharina
    Schlack, Katrin
    Weber, Manuel
    Herrmann, Ken
    Spanke, Maximilian
    Fendler, Wolfgang P.
    Hadaschik, Boris
    Kleesiek, Jens
    Schaefers, Michael
    Weckesser, Matthias
    Boegemann, Martin
    Rahbar, Kambiz
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (04) : 1200 - 1210
  • [42] Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer
    Fendler, Wolfgang P.
    Stuparu, Andreea D.
    Evans-Axelsson, Susan
    Luckerath, Katharina
    Wei, Liu
    Kim, Woosuk
    Poddar, Soumya
    Said, Jonathan
    Radu, Caius G.
    Eiber, Matthias
    Czernin, Johannes
    Slavik, Roger
    Herrmann, Ken
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (11) : 1786 - 1792
  • [43] Hematotoxicity after Radioligand Therapy with 177Lu-PSMA-617 in Patients with Metastastic Prostate Cancer
    Groener, Daniel
    Baumgarten, Justus
    Davis, Karen
    Happel, Christian
    Ngoc, Christina Nguyen
    Wichert, Jennifer
    Mader, Nicolai
    Mandel, Philipp
    Nikolaos, Tselis
    Gruenwald, Frank
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [44] 177Lu-PSMA Radioligand Therapy for Prostate Cancer (vol 58, pg 1196, 2017)
    Fendler
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (02) : 346 - 346
  • [45] Rechallenge 177Lu-PSMA radioligand therapy: First assessment in patients with metastatic prostate cancer
    Gafita, A.
    Eiber, M.
    Rauscher, I.
    Retz, M.
    Knorr, K.
    Heck, M.
    Gschwend, J.
    Schwaiger, M.
    Weber, W.
    Tauber, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S587 - S587
  • [46] Is Lu-177 PSMA radioligand therapy of prostate cancer safe for patients with single functioning kidney?
    Singh, A.
    Schuchardt, C.
    Kulkarni, H.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S413 - S414
  • [47] Early Experience of Rechallenge 177Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer
    Gafita, Andrei
    Rauscher, Isabel
    Retz, Margitta
    Knorr, Karina
    Heck, Matthias
    Wester, Hans-Juergen
    D'Alessandria, Calogero
    Weber, Wolfgang A.
    Eiber, Matthias
    Tauber, Robert
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (05) : 644 - 648
  • [48] 177Lu-PSMA-617 Radioligand Therapy in Patient With Prostate Cancer Sciatic Nerve Metastasis
    Tonnelet, David
    Edet-Sanson, Agathe
    Augusto, Laetitia
    Cabourg, Marine
    Thureau, Sebastien
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (12) : E668 - E669
  • [49] Defining the Position of [177Lu]Lu-PSMA Radioligand Therapy in the Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer: A Meta-analysis of Clinical Trials[177Lu]Lu-PSMA RLT in mCRPC: A Meta-analysis of Clinical TrialsC. Ciccarese et al.
    Chiara Ciccarese
    Matteo Bauckneht
    Luca Zagaria
    Giuseppe Fornarini
    Viria Beccia
    Francesco Lanfranchi
    Germano Perotti
    Giada Pinterpe
    Fortuna Migliaccio
    Giampaolo Tortora
    Lucia Leccisotti
    Gianmario Sambuceti
    Alessandro Giordano
    Orazio Caffo
    Roberto Iacovelli
    Targeted Oncology, 2025, 20 (1) : 103 - 112
  • [50] Factors predicting the early biochemical response to [177Lu]Lu-PSMA therapy in patients with metastatic castration resistant prostate cancer
    Al-Timimi, Ahmed
    Manafi-Farid, Reyhaneh
    Fallahi, Babak
    Beiki, Davood
    Askari, Emran
    Rezaei, Alireza
    Adinehpour, Zohreh
    Eftekhari, Mohammad
    IRANIAN JOURNAL OF NUCLEAR MEDICINE, 2022, 30 (02): : 115 - 121
12345